Robert J. Gould
Overview
Robert J. Gould received an average of $2M in total compensation, including $351K in salary, at Fulcrum Therapeutics from 2018 to 2023. Robert Gould also received an average of $2M at Epizyme from 2012 to 2015.
- 2023
- 2022
- 2020
- 2019
- 2018
- 2015
- 2014
- 2013
- 2012
Fulcrum TherapeuticsFormer Interim President and Chief Executive Officer
Fulcrum TherapeuticsFormer Interim President and Chief Executive Officer
Fulcrum TherapeuticsPresident and Chief Executive Officer
Fulcrum TherapeuticsPresident and Chief Executive Officer
Fulcrum TherapeuticsPresident and Chief Executive Officer
EpizymeFormer President and Chief Executive Officer
EpizymeFormer President and Chief Executive Officer
EpizymePresident and Chief Executive Officer
EpizymeChief Executive Officer
Source: SEC filings on April 19, 2024, April 29, 2021, April 29, 2020, April 15, 2016, April 15, 2015, and April 30, 2014.
Related executives
We found 19 more executives who work or worked at Fulcrum Therapeutics and Epizyme.
Alex Sapir
Fulcrum Therapeutics
Chief Executive Officer
Curtis Oltmans
Fulcrum Therapeutics
Chief Legal Officer
Mel Hayes
Fulcrum Therapeutics
Executive Vice President, Patient Affairs
Alan Musso
Fulcrum Therapeutics
Chief Financial Officer
Bryan Stuart
Fulcrum Therapeutics
Chief Executive Officer
Robert Bazemore
Epizyme
Chief Executive Officer
Jeffery Kutok
Epizyme
Chief Scientific Officer
Shefali Agarwal
Epizyme